EPI-7386
EPI-7386 is an N-terminal domain antiandrogen, or antagonist of the N-terminal domain of the androgen receptor, which is under development for the treatment of prostate cancer. The compound was developed as a successor of previous drugs in the EPI series such as EPI-001, ralaniten, and ralaniten acetate. EPI-7386 shows 20-fold higher antiandrogenic potency than ralaniten in vitro, as well as greater stability in human hepatocytes. It is planned to enter phase I clinical trials in 2020.
